TY - JOUR
T1 - Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions
AU - Wiseman, Sam M.
AU - Griffith, Obi L.
AU - Melck, Adrienne
AU - Masoudi, Hamid
AU - Gown, Allen
AU - Nabi, Ivan R.
AU - Jones, Steven J.M.
N1 - Funding Information:
S.M.W. is a Michael Smith Scholar and this work was supported by the Michael Smith Foundation For Health Research (MSFHR) and the University of British Columbia Department of Surgery. This work was supported in part by a University of British Columbia Department of Surgery Concept Award. O.L.G. was supported by the Canadian Institutes of Health Research and MSFHR. I.R.N. was supported by the Canadian Institutes of Health Research. S.J.M.J. was supported by MSFHR and the British Columbia Cancer Foundation.
PY - 2008/5
Y1 - 2008/5
N2 - Background: The aim of this study was to evaluate the diagnostic and prognostic utility of the type 1 growth factor receptor family in the management of differentiated thyroid cancer (DTC). Methods: Tissue microarrays consisting of 100 benign thyroid lesions and 105 malignant thyroid lesions stained for HER1, HER2, HER3, and HER4 were evaluated. Results: HER1, HER2, HER3, and HER4 were expressed in 76%, 2%, 57%, and 73% of DTC cases, respectively. HER1 and HER3 showed significantly increased expression, and HER4 showed significantly decreased expression, in DTC compared with benign thyroid lesions. HER3 expression correlated with the presence of lymph node metastasis, tumor type, and higher N stage; the expression of HER4 correlated with lower T stage. A classifier targeting benign versus malignant status with all 4 markers as potential predictors displayed an accuracy, sensitivity, and specificity of 66.8%, 63.5%, and 70.0%, respectively. Conclusions: For DTC, HER1, HER3, and HER4 have diagnostic and prognostic utility, and warrant further study as targets for cancer treatment.
AB - Background: The aim of this study was to evaluate the diagnostic and prognostic utility of the type 1 growth factor receptor family in the management of differentiated thyroid cancer (DTC). Methods: Tissue microarrays consisting of 100 benign thyroid lesions and 105 malignant thyroid lesions stained for HER1, HER2, HER3, and HER4 were evaluated. Results: HER1, HER2, HER3, and HER4 were expressed in 76%, 2%, 57%, and 73% of DTC cases, respectively. HER1 and HER3 showed significantly increased expression, and HER4 showed significantly decreased expression, in DTC compared with benign thyroid lesions. HER3 expression correlated with the presence of lymph node metastasis, tumor type, and higher N stage; the expression of HER4 correlated with lower T stage. A classifier targeting benign versus malignant status with all 4 markers as potential predictors displayed an accuracy, sensitivity, and specificity of 66.8%, 63.5%, and 70.0%, respectively. Conclusions: For DTC, HER1, HER3, and HER4 have diagnostic and prognostic utility, and warrant further study as targets for cancer treatment.
KW - Thyroid cancer
KW - Tissue microarray
KW - Type 1 growth factor receptor family
UR - https://www.scopus.com/pages/publications/42149102584
U2 - 10.1016/j.amjsurg.2008.01.008
DO - 10.1016/j.amjsurg.2008.01.008
M3 - Article
C2 - 18424286
AN - SCOPUS:42149102584
SN - 0002-9610
VL - 195
SP - 667
EP - 673
JO - American journal of surgery
JF - American journal of surgery
IS - 5
ER -